SCANDARE TNBC - EGA European Genome-phenome Archive

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001416	SCANDARE (NCT03017573) is a multicentric biobanking study, enrolling adult patients with newly diagnosed head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC), ovarian and cervical cancer. Tumor tissue and blood samples are collected at several time points during patient's journey, including at diagnosis, post-neoadjuvant chemotherapy in case of neoadjuvant treatment, at surgery, at recurrence and at disease progression following treatment initiated at recurrence. Since its launch in 2017 at Institut Curie, SCANDARE has enabled the longitudinal collection and preservation of samples for in-depth analyses. Here, we describe molecular alterations in 124 frozen samples (n=84 at baseline and n=40 paired at post-NAC surgery) from 91 TNBC patients using total RNAseq technology, with FASTQ files deposited in the dataset.	Illumina NovaSeq 6000	124
EGAD50000001661	SCANDARE (NCT03017573) is a multicentric biobanking study, enrolling adult patients with newly diagnosed head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC), ovarian and cervical cancer. Tumor tissue and blood samples are collected at several time points during patient's journey, including at diagnosis, post-neoadjuvant chemotherapy in case of neoadjuvant treatment, at surgery, at recurrence and at disease progression following treatment initiated at recurrence. Since its launch in 2017 at Institut Curie, SCANDARE has enabled the longitudinal collection and preservation of samples for in-depth analyses. Here, we describe molecular alterations in 247 frozen samples at baseline and 138 germline DNA from 139 TNBC patients using WES technology, with FASTQ files deposited in the dataset.	Illumina NovaSeq 6000	385
EGAD50000001662	SCANDARE (NCT03017573) is a multicentric biobanking study, enrolling adult patients with newly diagnosed head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC), ovarian and cervical cancer. Tumor tissue and blood samples are collected at several time points during patient's journey, including at diagnosis, post-neoadjuvant chemotherapy in case of neoadjuvant treatment, at surgery, at recurrence and at disease progression following treatment initiated at recurrence. Since its launch in 2017 at Institut Curie, SCANDARE has enabled the longitudinal collection and preservation of samples for in-depth analyses. Here, we describe molecular alterations in 108 FFPE samples at baseline and 108 germline DNA from 108 TNBC patients using WGS technology, with FASTQ files deposited in the dataset.	Illumina NovaSeq X	216
EGAD50000001849	SCANDARE (NCT03017573) is a multicentric biobanking study, enrolling adult patients with newly diagnosed head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC), ovarian and cervical cancer. Tumor tissue and blood samples are collected at several time points during patient's journey, including at diagnosis, post-neoadjuvant chemotherapy in case of neoadjuvant treatment, at surgery, at recurrence and at disease progression following treatment initiated at recurrence. Since its launch in 2017 at Institut Curie, SCANDARE has enabled the longitudinal collection and preservation of samples for in-depth analyses. Here, we describe molecular alterations in 251 frozen samples at baseline from 143 TNBC patients using shallow WGS technology, with FASTQ files deposited in the dataset.	Illumina NovaSeq 6000	251

Publications	Citations
Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatment. Torossian N, Gabriel M, Papoutsoglou P, Foretek D, Brochard C, Kamal M, Ramdani L, Lamy C, Lecerf C, Halladjian M, Dupain C, Lafleur J, Aguilar-Mahecha A, Basik M, Vincent-Salomon A, Tourneau CLE, Roman-Roman S, Gautheret D, Morillon A. NAR Cancer 7: 2025 zcaf036	2
An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation. Hofer I, Kieffer Y, Mencattini A, Croizer H, Mhaidly R, Descroix S, Le Tourneau C, Kamal M, Lamy C, Bonneau C, Cottu PH, Vincent-Salomon A, Martinelli E, Mechta-Grigoriou F, Parrini MC. Cancer Res 86: 2026 1054-1072	5
Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer. Pasanisi J, Lamy C, Lecompte L, Vacher S, Schwartz M, Hamza A, Caputo SM, Ibadioune S, Courtois L, Berger F, Cockenpot V, Baulande S, Pierga JY, Callens C, Melaabi S, Colas C, Pasmant E, Kamal M, Dupain C, Servant N, Le Tourneau C, Bièche I. NPJ Breast Cancer 12: 2026 39	5
E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer. Djerroudi L, Mhaidly R, Kieffer Y, Damei I, Croizer H, Selvarasa V, Gentric G, Fuhrmann L, Goncalves A, Caly M, Richardot C, Leclere R, Laas E, Malhaire C, Cao K, Houthuijzen JM, Kloosterman P, Jonkers J, Benoist C, Renault V, Bidard FC, Vincent-Salomon A, Mechta-Grigoriou F. Nat Commun 17: 2026 9249	0
Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy. Cabel L, Lamy C, Abbott CW, Keough KC, Pouget N, Pierga JY, Sablin MP, Flavius J, Bronzini T, Laas E, Darrigues L, Li B, Navarro FCP, Féron JG, Fourchotte V, Bonneau C, Vincent-Salomon A, Boyle SM, Chen RO, Le Tourneau C, Bidard FC. ESMO Open 11: 2026 108334	0